Oxdralazine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413868

CAS#: 17259-75-5 (free base)

Description: Oxdralazine is a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment.

Chemical Structure

img
Oxdralazine
CAS# 17259-75-5 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 413868
Name: Oxdralazine
CAS#: 17259-75-5 (free base)
Chemical Formula: C8H15N5O2
Exact Mass: 213.12
Molecular Weight: 213.240
Elemental Analysis: C, 45.06; H, 7.09; N, 32.84; O, 15.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 17259-75-5 (free base); 27464-23-9 (2HCl)  

Synonym: Oxdralazine; DL150; DL-150; DL 150; L6150; L-6150; L 6150

IUPAC/Chemical Name: 2,2'-((6-Hydrazino-3-pyridazinyl)imino)diethanol

InChi Key: POFDNYKJHWKGDU-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H15N5O2/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15/h1-2,14-15H,3-6,9H2,(H,10,11)

SMILES Code: NNC1=NN=C(N(CCO)CCO)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 213.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Salvadeo A, Villa G, Segagni S, Piazza W, Criscuolo D. Comparative study of oxdralazine and dihydralazine in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):372-6. PMID: 7030978.

2: Salvadeo A, Villa G, Segagni S, Galli F, Criscuolo D. A crossover trial of oxdralazine in hypertension. J Clin Pharmacol. 1983 Apr;23(4):155-60. doi: 10.1002/j.1552-4604.1983.tb02719.x. PMID: 6345596.

3: Moskowitz RM, Cohn JN. Hemodynamic effects of oxdralazine and hydralazine in hypertension. Clin Pharmacol Ther. 1980 Jun;27(6):773-8. doi: 10.1038/clpt.1980.109. PMID: 7379444.

4: Salvadeo A, Villa G, Segagni S, Criscuolo D. Long-term study of oxdralazine in hypertensive patients. Arzneimittelforschung. 1979;29(11):1753-5. PMID: 396926.

5: Bartoli E, Faedda R, Arras S, Satta A, Soggia G. Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment. J Clin Pharmacol. 1979 Nov- Dec;19(11-12):751-7. doi: 10.1002/j.1552-4604.1979.tb01647.x. PMID: 536472.

6: de Leeuw PW, van Soest GA, Birkenhäger WH. Aldosterone response to antihypertensive treatment. Clin Exp Hypertens A. 1982;4(9-10):1913-21. doi: 10.3109/10641968209061649. PMID: 6291819.

7: Glorioso S, Romeo B, Borsatti A, Todesco S. Valutazione clinica comparativa dell'efficacia e della tollerabilità del nuovo antiipertensivo DL 150 IT somministrato da solo ed in associazione a reserpina o propranololo [Comparative clinical evaluation of the effectiveness and tolerance of a new antihypertensive agent, DL 150 IT, administered alone and in combination with reserpine or propranolol]. Clin Ter. 1977 Nov 15;83(3):279-99. Italian. PMID: 603983.

8: Kawashima K, Watanabe TX, Sokabe H. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats. Jpn J Pharmacol. 1980 Feb;30(1):116-8. doi: 10.1254/jjp.30.116. PMID: 6995653.

9: Watanabe TX, Shiono K, Saito K, Sokabe H. Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. Jpn J Pharmacol. 1978 Jun;28(3):413-22. doi: 10.1254/jjp.28.413. PMID: 702944.

10: Maseri A, Pesola A, L'Abbate A, Contini C, Magini G. Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. J Int Med Res. 1976;4(6):402-9. doi: 10.1177/030006057600400605. PMID: 1027634.